Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $171.98 USD
Change Today -3.30 / -1.88%
Volume 2.2M
ALXN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Open
$170.01
Previous Close
$175.28
Day High
$175.76
Day Low
$168.37
52 Week High
07/23/15 - $208.88
52 Week Low
05/6/15 - $150.06
Market Cap
38.9B
Average Volume 10 Days
2.1M
EPS TTM
$3.28
Shares Outstanding
226.2M
EX-Date
--
P/E TM
52.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXION PHARMACEUTICALS INC (ALXN)

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

2,273 Employees
Last Reported Date: 02/6/15
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $696.1K
Co-Founder, Chairman of The Board and Consult...
Total Annual Compensation: $1.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $715.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $650.0K
Chief Strategy & Portfolio Officer and Execut...
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2014.

alexion pharmaceuticals inc (ALXN) Key Developments

U.S. Food and Drug Administration Extends the Prescription Drug User Fee Act Date of Alexion Pharmaceuticals, Inc. for its Priority Review of Biologics License Application for Kanuma

Alexion Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its Priority Review of the company’s Biologics License Application (BLA) for Kanuma (sebelipase alfa), an investigational enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D). The previously disclosed September 8, 2015 PDUFA date has been extended by the standard extension period of three months. In response to a recent request from the FDA, Alexion submitted additional Chemistry, Manufacturing and Controls (CMC) information. Due to the timing of this submission, the FDA extended the PDUFA date to allow additional time for review of the new information. The FDA has not asked for additional clinical data.

European Commission Grants Marketing Authorization for Alexion Pharmaceuticals, Inc.'s Kanuma (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency

Alexion Pharmaceuticals, Inc. announced that the European Commission (EC) has approved Kanuma™ (sebelipase alfa) for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase deficiency (LAL-D). Kanuma, an innovative ERT, is the first approved treatment in the European Union for patients with LAL-D, a genetic and progressive ultra-rare metabolic disease in which patients suffer multi-organ damage and premature death. Alexion expects to begin serving patients in Germany in October and is now commencing reimbursement processes with healthcare authorities in each of the major European countries. LAL-D is a genetic, chronic and progressive metabolic disease in which infants, children and adults suffer multi-organ damage and premature death. It is an ultra-rare disease, which is defined as a disease that affects fewer than 20 patients per one million of the general population. Patients with LAL-D often experience a rapid onset of life-threatening disease manifestations, and similar to other liver diseases, many patients may be asymptomatic until they experience a severe consequence of the disease. LAL-D is caused by genetic mutations that result in a marked decrease or loss in LAL enzyme activity in the lysosomes across multiple body tissues, leading to the chronic build-up of cholesteryl esters and triglycerides in the liver, blood vessel walls and other tissues. Kanuma is a enzyme replacement therapy (ERT) designed to address the underlying cause of LAL-D. The approval of Kanuma applies to all 28 EU member states as well as Iceland, Norway, and Lichtenstein and was granted under the accelerated assessment procedure. The decision follows the June 2015 positive opinion granted by the Committee for Medicinal Products for Human Use (CHMP). In addition, the U.S. Food and Drug Administration granted Breakthrough Therapy designation for Kanuma for LAL Deficiency presenting in infants and accepted the Kanuma BLA (Biologics License Application) for Priority Review.

Alexion Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year of 2015

Alexion Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company announced total revenues of $636,210,000 compared to $512,495,000 for the same period a year ago. Operating income was $181,082,000 compared to $218,849,000 for the same period a year ago. Income before income taxes was $177,292,000 compared to $218,646,000 for the same period a year ago. Net income was $170,215,000 compared to $166,495,000 for the same period a year ago. Earnings per common share, diluted were $0.83 compared to $0.83 for the same period a year ago. Non-GAAP net income was $297,732,000 compared to $229,072,000 for the same period a year ago. Non-GAAP earnings per share, diluted were $1.44 compared to $1.12 for the same period a year ago. For the six months, the company announced total revenues of $1,236,543,000 compared to $1,079,111,000 for the same period a year ago. Operating income was $284,789,000 compared to $428,352,000 for the same period a year ago. Income before income taxes was $284,237,000 compared to $430,557,000 for the same period a year ago. Net income was $261,538,000 compared to $325,849,000 for the same period a year ago. Earnings per common share, diluted were $1.29 compared to $1.62 for the same period a year ago. Non-GAAP net income was $562,689,000 compared to $541,671,000 for the same period a year ago. Non-GAAP earnings per share, diluted were $2.72 compared to $2.62 for the same period a year ago. The company revised earnings guidance for the full year of fiscal 2015. The company is revising upward its revenue guidance for 2015 from the previous range of $2.55 billion to $2.6 billion, now to the higher and narrower range of $2.6 billion to $2.62 billion, which includes an approximately negative 6%, or $160 million, foreign exchange impact compared to 2014 exchange rates. The company is reducing its 2015 non-GAAP tax rate guidance to the lower range of 3% to 4%, from the previous range of 7% to 9%. Interest expense expected to be $55 million. The company is revising 2015 non-GAAP EPS guidance to the range of $4.70 to $4.80 per share, from the previous range of $5.60 to $5.80 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $171.98 USD -3.30

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,799 GBp -57.00
Dr Reddy's Laboratories Ltd 4,053 INR 0.00
Sigma-Aldrich Corp $139.46 USD -0.10
Symrise AG €52.41 EUR -0.80
United Therapeutics Corp $149.21 USD -0.75
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 59.9x
Price/Sales 14.8x
Price/Book 4.6x
Price/Cash Flow 66.9x
TEV/Sales 14.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit www.alexionpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.